Effects of probucol on restenosis after percutaneous coronary intervention: a systematic review and meta-analysis

Restenosis after percutaneous coronary intervention (PCI) is a remained clinical problem which limits long-term success of PCI. Although there was recognition that probucol in treating restenosis after percutaneous transluminal coronary angioplasty, the efficacy of probucol on restenosis after stent...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2015-04, Vol.10 (4), p.e0124021-e0124021
Main Authors: Liu, Jichen, Li, Menghao, Lu, Hao, Qiao, Weiguang, Xi, Dan, Luo, TianTian, Xiong, Haowei, Guo, Zhigang
Format: Article
Language:English
Subjects:
Analysis
Angiography
Angioplasty
Anticholesteremic Agents - pharmacology
Anticholesteremic Agents - therapeutic use
Balloon angioplasty
Blood vessels
Cardiovascular Agents - pharmacology
Cardiovascular Agents - therapeutic use
Clinical trials
Combined Modality Therapy
Coronary Disease - therapy
Humans
Implantation
Implants
Incidence
Intervention
Lipids
Medical research
Meta-analysis
Patients
Percutaneous Coronary Intervention
Probucol
Probucol - pharmacology
Probucol - therapeutic use
Restenosis
Risk reduction
Stenosis
Stents
Studies
Surgical implants
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Restenosis after percutaneous coronary intervention (PCI) is a remained clinical problem which limits long-term success of PCI. Although there was recognition that probucol in treating restenosis after percutaneous transluminal coronary angioplasty, the efficacy of probucol on restenosis after stent-implantation is controversial. So this meta-analysis was conducted to investigate the association between probucol and late restenosis. Articles were assessed by four trained investigators, with divergences resolved by consensus. PubMed, EMBASE, ScienceDirect and the Cochrane Central Register of clinical trials were searched for pertinent studies. Inclusion criteria were random allocated to treatment and a comparison of probucol-treated patients and control patients (not treated with lipid-lowering drug) undergoing PCI. Fifteen studies with 859 subjects were analyzed. Major outcome, binary angiographic restenosis defined as >50% stenosis upon follow-up angiography, was significantly decreased with probucol treatment (RR = 0.59 [0.43, 0.80] among vessels, P = 0.0007; and RR = 0.52 [0.40, 0.68] among patients, P
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0124021